## SENTARA HEALTH PLANS <br> PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; fax to $1-800-750-9692$. No additional phone calls will be necessary if all information (including phone and fax $\# s$ ) on this form is correct. If information provided is not complete, correct, or legible, authorization may be delayed.

Drug Requested: Furoscix ${ }^{\circledR}$ (furosemide)
MEMBER \& PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.
Member Name:
Member Sentara \#: $\qquad$ Date of Birth: $\qquad$
Prescriber Name: $\qquad$
Prescriber Signature: $\qquad$ Date: $\qquad$
Office Contact Name: $\qquad$
Phone Number: $\qquad$ Fax Number: $\qquad$
DEA OR NPI \#: $\qquad$
DRUG INFORMATION: Authorization may be delayed if incomplete.
Drug Form/Strength: $\qquad$
Dosing Schedule: $\qquad$

## Length of Therapy:

$\qquad$
Diagnosis: $\qquad$ ICD Code: $\qquad$
Weight: Date: $\qquad$
Quantity Limit: 2 on-body infusors per fluid overload episode (max of 2 per fill)
CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

Initial Authorization: 6 months

- Member is 18 years of age or older
- Member has a diagnosis of New York Heart Association (NYHA) Class II or III chronic heart failure
- Member is experiencing congestion due to fluid overload
- Member does NOT have anuria or hepatic cirrhosis or ascites
- Member does NOT have a hypersensitivity to furosemide or medical adhesives
- Member does NOT have acute pulmonary edema
- Prescriber attests, Furoscix will NOT be prescribed for an emergency situation
- Prescriber attests the member requires a non-oral route of administration of a loop diuretic for congestion due to fluid overload in chronic heart failure
- Prescriber attests the member will be monitored outpatient for fluid, electrolyte, and metabolic abnormalities

Reauthorization: 12 months. Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

- Member must have disease improvement and/or stabilization OR improvement in the slope of decline (e.g., improvement in signs/symptoms of fluid overload - edema, dyspnea, rapid weight gain)
- Member has NOT experienced any treatment-restricting adverse effects (e.g., fluid, electrolyte, or metabolic abnormalities, worsening renal function, ototoxicity, acute urinary retention)

Not all drugs may be covered under every Plan. If a drug is non-formulary on a Plan, documentation of medical necessity will be required.
**Use of samples to initiate therapy does not meet step edit/ preauthorization criteria. ** *Previous therapies will be verified through pharmacy paid claims or submitted chart notes. *

[^0]
[^0]:    *Approved by Pharmacy and Therapeutics Committee: 2/16/2023
    REVISED/UPDATED/REFORMATTED: 3/09/2023

